Galapagos shows that the fittest can survive
Interviewee/Contributor
Piet Wigerinck and Walid Abi-Saab
Organisation
Galapagos NV
Drug discovery
Exploring new business models for antibiotics
Interviewee/Contributor
Heather Graz
Organisation
Neem Biotech Ltd
Vivoryon Therapeutics tests Alzheimer's drug
Interviewee/Contributor
Ulrich Dauer
Organisation
Vivoryon Therapeutics AG
Gut microbiota is new frontier in CNS research
Interviewee/Contributor
Peter Charlish
Organisation
MedNous
Taking on the Alzheimer's conundrum
Interviewee/Contributor
Reisa Sperling
Organisation
Harvard Medical School
Revisiting antibody-drug conjugates
Interviewee/Contributor
Chris Martin
Organisation
ADC Therapeutics SA
Finding a treatment for mesothelioma
Interviewee/Contributor
Rob Meijer
Organisation
Amphera BV
Dual inhibition of intracellular enzymes
Interviewee/Contributor
Tara Rheault Margot MacDonald-Berko
Organisation
Verona Pharma Plc
ASCO 2019: Successes and setbacks mark the cancer meeting
Interviewee/Contributor
Bruno Pagliara
Organisation
On-kòs Pharma Consulting
Combining biologics and small molecules for cancer
Interviewee/Contributor
Amrik Basran
Organisation
Avacta Life Sciences